PhRMA Backs Merck In 3rd Circ. Over Nixed Fosamax Claims
Law360, New York (November 6, 2015, 12:05 PM EST) -- Pharmaceutical Research and Manufacturers of America has asked the Third Circuit to affirm the dismissal of any multidistrict litigation claims over Merck’s osteoporosis drug Fosamax predating a labeling revision by the U.S. Food and Drug Administration, claiming the agency’s previous position clearly barred those claims.
PhRMA, which counts Merck Sharp & Dohme Corp., Pfizer Inc. and other major drug manufacturers as members, told the appellate court on Wednesday that a New Jersey federal judge correctly had dismissed all injury claims from the MDL that came prior to an FDA task force’s report linking femur fractures to bisphosphonates, which include the active...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!